Mindray's 2020 financial report: revenue of 21.026 billion and net profit increased by 42%. Research...

Finishinghaon

On April 28, Mindray Medical (300760.

The report shows that in 2020, Mindray Medical’s operating income is approximately 21.

Previously, Mindray Medical proposed to increase the proportion of overseas business to 70%.

Regarding the main performance drivers in 2020, Mindray said that in 2020, with the global outbreak of the new crown epidemic, monitors, ventilators, infusion pumps, and portable color Doppler ultrasound and mobile DR for medical imaging services for life information and support services The demand for life information and support services has increased significantly, and the driving effect on life information and support services is particularly significant.

Starting from the second quarter of 2020, the company began to export COVID-19 IgG/IgM antibody detection reagents to overseas markets, which made up for part of the impact of the epidemic on the in vitro diagnostic business.

After the test of this round of the epidemic, the company's brand influence and recognition in the domestic and international markets have been greatly improved, and breakthroughs have been achieved in many high-end market customer groups, bringing more opportunities for the company's future growth.

At the same time, the company continued to strengthen internal management to improve operating efficiency, and was affected by the reduction in marketing and travel during the epidemic period, and its operating performance showed a healthy and good growth trend.

As of today's close, Mindray Medical has offered 456 yuan per share, with a market value of 554.

Mindray Medical was listed on the New York Stock Exchange in 2006 and returned to China from privatization in 2016, with a market value of 23 billion yuan ($3.

It is worth noting that Mindray released the first quarter report of 2021 in the same period today.

Attachment· sina.